Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer Phase Ib (China only): Approximately 90 patients Phase Ⅱ (globally): Approximately 78 evaluable patients; addition of at least 6 patients in Safety Run-in (US only)

Trial Details

NCT ID
NCT04270591
Phase
PHASE1 / PHASE2
Sponsor
Haihe Biopharma Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Glumetinib
Locations (sample)
  • Louisville, Kentucky, United States|38.25424,-85.75941
  • Louisville, Kentucky, United States|38.25424,-85.75941
  • Hefei, Anhui, China|31.86389,117.28083
  • Hefei, Anhui, China|31.86389,117.28083
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Provide informed consent voluntarily.
  • Male and female patients ≥ 18 years of age (or having reached the age of majority according to local laws and regulations, if the age is \> 18 years).
  • Histologically or cytologically confirmed diagnosis of NSCLC including PSC.
  • Patients with stage IIIb or IIIc NSCLC who are not candidates for definitive surgical resection or concurrent chemoradiation or patients with stage…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →